JPRN-UMIN000010150已完成1 期
Phase I Study of Intratumoral Administration of HF10, Oncolytic Herpes Simplex Virus Type 1, in Patients with Advanced Unresectable Pancreatic Cancer - Clinical Study using HF10 against Advanced Unresectable Pancreatic Cancer
agoya University School of Medicine0 个研究点目标入组 9 人开始时间: 2013年3月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 9
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patient with: -Ascites. pleural infusion. -Infectious disease. -Any other cancer. -Brain metastasis. -hypersensitivity to live-virus vaccine. Pregnant or breast feeding patient.
研究者
相似试验
已完成
1 期
Phase I study of intratumoral injection of HF10, naturally occurring mutant of herpes simplex virus type 1on-CNS malignant solid tumorJPRN-UMIN000007263Mie University Graduate School of Medicine9
已完成
1 期
A Phase I study of intratumoral administration of TDM-812 in patients with treatment-resistant breast cancer (RPN2siRNA)treatment-resistant breast cancerJPRN-UMIN000016790ational Cancer Center30
进行中（未招募）
1 期
Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patientsEUCTR2020-003299-42-PLPhilogen S.p.A.40
进行中（未招募）
1 期
Intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patientsPatients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), basal cell carcinoma (BCC) or cutaneous squamous cell carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery according to the evaluation of a local interdisciplinary tumor board or who refuse surgery and for whom an histological evaluation is available according to international guidelinesMedDRA version: 20.0Level: PTClassification code 10004146Term: Basal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-003299-42-DEPhilogen S.p.A.40
已完成
1 期
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial LesionsRefractory Head and Neck CancerSquamous Cell Carcinoma, SkinCarcinoma of the BreastMalignant MelanomaNCT01017185Takara Bio Inc.28